Validation of a panel of fibroblast activation protein expressing cell line derived xenograft models as a platform for the development of targeted radioligand therapeutics

lutetium Lu 177 rofapitide tetraxetan (AAA614) - Novartis

https://www.abstractsonline.com/pp8/#!/21436/presentation/3977

Michael Batey; James Suchy; Taylor Hotz; Michael Milhollen; Kayla Duval; Jackson Chan; Karen Gelinas; Michael Bruce; Michelle Petrozzi; William Maccuaig; Neil Rollins; Jennifer Tavares; Erin Snay; Kyeara Mack-Henry; Soumya Ullas

Mar 18, 2026